Q-omics provides the consensus-scored GOLGA2 profile across patient tissues and cancer cell-line models. GOLGA2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GOLGA2 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, GOLGA2 RNA expression shows 20,539 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, LUAD, and KIRP as cancer lineages where GOLGA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA2 survival associations across molecular data types. GOLGA2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA2 RNA expression–survival associations across cancer types. High GOLGA2 expression shows unfavorable associations in ACC, BLCA, LGG, UVM and READ, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GOLGA2 RNA expression.
This table summarizes GOLGA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GOLGA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA2 shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC, BRCA, CHOL and STAD. The LUAD box plot shows higher GOLGA2 RNA expression in tumor versus normal tissue (log2 FC = +0.499, t-test p < 0.001).
This table shows molecular features associated with GOLGA2 in patient tissues and cancer cell lines. In patient samples, GOLGA2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
